Arrowhead Pharmaceuticals director sells $173,920 in stock By Investing.com

Adeoye Y. Olukotun, a director at Arrowhead Pharmaceuticals, Inc. (), recently sold shares of the company’s common stock.

On August 18, 2026, Mr. Olukotun disposed of 2,000 shares at a price of $86.96 per share, totaling $173,920. The sale comes as Arrowhead’s stock trades near its 52-week high of $95.49, following a remarkable 322% return over the past year. The stock currently trades at $87.47, giving the company a market cap of $12.36 billion, though InvestingPro analysis suggests the shares may be overvalued at current levels.

Following this transaction, Mr. Olukotun beneficially owns 31,600 shares of Arrowhead Pharmaceuticals common stock. This figure includes previously reported shares of common stock underlying Restricted Stock Units granted to Mr. Olukotun, a portion of which remain subject to certain vesting conditions. For deeper insights into ARWR’s valuation and performance, InvestingPro offers 14 additional ProTips and comprehensive financial metrics.

In other recent news, Arrowhead Research reported its fiscal third-quarter 2026 revenue, which significantly surpassed expectations. The company achieved $75.2 million in revenue, exceeding Wall Street’s forecast of $52.7 million. Despite this revenue boost, Arrowhead’s net loss widened to $1.36 per share, compared to the anticipated loss of $1.20 per share. The revenue increase was largely attributed to collaboration income and the initial commercial sales of its newly approved drug, REDEMPLO. The momentum for this drug appears strong, supported by promising late-stage data for a larger follow-on indication. These developments highlight Arrowhead’s growing market presence and successful product launch. Investors seemed to focus on the stronger-than-expected sales figures as a positive indicator for the company’s future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.